LAS VEGAS, October 1, 2009 – Canon U.S.A., Inc., a leader in digital imaging solutions, today introduced the CX-1 Mydriatic/Non-Mydriatic Digital Retinal Camera1 at Vision Expo West. In addition to the CX-1, Canon will showcase its complete line of ophthalmic solutions in the Canon booth (MS6063) at the Sands Expo Center in Las Vegas (October 1st– 3rd, 2009).
The CX-1 is the Company's first fully hybrid digital retinal camera with both mydriatic and non-mydriatic modes. With one-touch, the operator can automatically switch between mydriatic and non-mydriatic modes, effortlessly utilizing different functions within seconds and performing several concurrent ocular tests.
The CX-1 is the world's first non-mydriatic digital camera to take FAF (Fundus Autofluorescence) photography. To date, FAF photography was only possible in mydriatic mode. Detecting Autofluorescence of the retina is an important indication of the retina's health. Using the non-mydriatic mode not only saves time and resources, it also can make the diagnostic procedure more comfortable for the patient.
"As a pioneer and leader in the field of retinal imaging for more than 30 years, Canon is proud to introduce the world's first non-mydriatic digital retinal camera to take FAF photography, the CX-1 Mydriatic/Non-Mydriatic Digital Retinal Camera," said Tsuneo Imai, senior director and general manager, Medical Systems Division, Canon U.S.A.
"At Vision Expo West, Canon will demonstrate its commitment to helping make it simple and convenient for ophthalmic professionals to provide quality care to their patients by providing the latest digital imaging technology," noted Imai.
Canon's EOS camera technology, with its renowned image processing capabilities, is adapted exclusively for medical use in the CX-1, providing up to 15.1 megapixel resolution. The CX-1 is capable of delivering clear and detailed diagnostic images for virtually immediate review. The single onboard digital camera handles five different photography modes with ease, including non-mydriatic FAF, Color, Red-free, Cobalt and Fluorescein angiography photography.
TThe Retinal Imaging Control Software that comes with the CX-1 puts tools for comprehensive study management, image capture controls and easy viewing at your fingertips. The intuitive graphical interface is simple and straightforward to use. The PC-based software provides quick input and access to all information and images required to assist in patient diagnosis, and data can be easily saved to various external media.
Canon offers and markets a full line of digital imaging solutions for the ophthalmic world, including Non-Mydriatic and Mydriatic Retinal cameras, and full auto-tonometer and full auto-ref keratometers, all of which will be on display at the show. In addition to the CX-1, the Canon product line includes:
For more information about Canon ophthalmic devices and solutions, please go to www.usa.canon.com/eye-care.
Canon U.S.A., Inc., is a leading provider of consumer, business-to-business, and industrial digital imaging solutions. Its parent company, Canon Inc. (NYSE:CAJ), a top patent holder of technology, ranked third overall in the U.S. in 2008†, with global revenues of US $45 billion, is listed as number seven in the computer industry on Fortune Magazine's World's Most Admired Companies 2008 list, and is on the 2008 BusinessWeek list of "Top 100 Brands." At Canon, we care because caring is essential to living together in harmony. Founded upon a corporate philosophy of Kyosei – "all people, regardless of race, religion or culture, harmoniously living and working together into the future" – Canon U.S.A. supports a number of social, youth, educational and other programs, including environmental and recycling initiatives. Additional information about these programs can be found at www.usa.canon.com/kyosei. To keep apprised of the latest news from Canon U.S.A., sign up for the Company's RSS news feed by visiting www.usa.canon.com/rss.
1 The CX -1 Mydriatic/Non-Mydriatic Digital Retinal Camera has not yet been cleared by the FDA. This device has a 510(k) application pending with the FDA. Not for sale or lease in the United States.
2 OPTOPOL Technology S.A. SPOCT HR has not yet been cleared by the FDA. This device has a 510(k) application pending with the FDA. Not for sale or lease in the United States.
†Based on weekly patent counts issued by the United States Patent and Trademark Office
Specifications subject to change without notice.
All referenced product names, and other marks, are trademarks of their respective owners.